Cantitate/Preț
Produs

RNA Technologies in Cardiovascular Medicine and Research

Editat de Volker A. Erdmann, Wolfgang Poller, Jan Barciszewski
en Limba Engleză Hardback – 8 iul 2008
In this book the authors review the field and explore the potential role of RNAi and other RNA technologies in cardiovascular medicine and research. They highlight the impressive recent progress but also the hurdles that still must be overcome before this promising technology is finally ready for translation and clinical use.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 157065 lei  6-8 săpt.
  Springer Berlin, Heidelberg – 18 oct 2010 157065 lei  6-8 săpt.
Hardback (1) 157603 lei  6-8 săpt.
  Springer Berlin, Heidelberg – 8 iul 2008 157603 lei  6-8 săpt.

Preț: 157603 lei

Preț vechi: 165898 lei
-5% Nou

Puncte Express: 2364

Preț estimativ în valută:
30159 31729$ 24970£

Carte tipărită la comandă

Livrare economică 14-28 ianuarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783540787082
ISBN-10: 3540787089
Pagini: 376
Ilustrații: XIV, 358 p. 55 illus.
Dimensiuni: 155 x 235 x 30 mm
Greutate: 0.66 kg
Ediția:2008
Editura: Springer Berlin, Heidelberg
Colecția Springer
Locul publicării:Berlin, Heidelberg, Germany

Public țintă

Research

Descriere

In this book the authors review the field and explore the potential role of RNAi and other RNA technologies in cardiovascular medicine and research. They highlight the impressive recent progress but also the hurdles that still must be overcome before this promising technology is finally ready for translation and clinical use.

Cuprins

Preface.- Part I - MicroRNA.- An overview of microRNA. MicroRNAs and their potential. miRNAs and their emerging role in cardiac hypertrophy. MicroRNAs and the control of heart pathophysiology. MicroRNA systems biology.- Part II - RNA interference.- Targeting viral heart disease by RNA interference. Design of siRNAs and shRNAs for RNA interference: possible clinical applications. RNA interference and microRNA modulation for the treatment of cardiac disorders. Cardiac delivery of nucleic acids by transcriptional and transductional targeting of adeno-associated viral vectors.- Part III - Ribozymes.- Characterization of hammerhead ribozymes potentialy suitable for the treatment of hyperproliferative vascular diseases. Applications of ribozymes and pyrrole-imidazole polyamides for cardiovascular and renal diseases.- Part IV. - Noncoding, aptamer and antisense RNAs.- Noncoding RNAs in human diseases. Aptamers and siRNAs in cardiovascular disease. Nucleic Acid Aptamers for Cardiovascular Therapeutics. NFkB decoy oligodeoxynucleotide-based therapy in cardiovascular diseases. Antisense therapy for restenosis following percutaneous coronary intervention.Toxic RNA in pathogenesis of human neuromuscular disorders.

Textul de pe ultima copertă

Cardiovascular disease is the number one cause of death worldwide. In 2005 17.5 million people, representing 30% of all global deaths, died of cardiovascular disease. For this reason every effort needs to be made to improve the early diagnosis and treatment procedures for combating this disease. This book - edited by Professors Erdmann and Barciszewski, both internationally recognised experts in the field of RNA molecular biology, and Professor Poller, an internationally respected expert in cardiology - will offer more than an introduction to these fields. More importantly, it will also lead the reader to the newest developments in RNA methods and technologies and show how they are currently employed for the diagnosis and treatment of cardiovascular disease. This book is also a must for all those interested in knowing more about the molecular medicine of tomorrow and how it will be revolutionised by its newest approach - RNA technologies.

Caracteristici

Currently no comprehensive overview on potential and challenges of RNAi and other RNA technologies for basic cardiovascular biology and for the clinical management of patients with cardiovascular disorders
Book will be comprehensive in that it does not only treat the phenomenon of RNAi in all its facets (as most recently published books), but does explicitly cover the many other aspects of the “RNA World” (pathogenic and therapeutic potential of microRNAs, aptamer technology, etc.), too
With this significantly broadened scope as compared to currently existing books it appears to be an urgently needed new publication
Includes supplementary material: sn.pub/extras